IPAR

Publicly Available Assessment Report for a
Veterinary Medicinal Product

Gamrozyne 150 mg/ml Solution for Injection for Cattle, Sheep and Pigs

PRODUCT SUMMARY

EU Procedure number	IE/V/0883/001/DC
Name, strength and pharmaceutical form	Gamrozyne 150 mg/ml Solution for Injection for Cattle, Sheep and Pigs
Active substance(s)	Gamithromycin
Applicant	Bimeda Animal Health Limited, Unit 2, 3 & 4 Airton Close, Airton Road, Tallaght, Dublin 24, Ireland D24 FH9V
Legal basis of application	Generic application in accordance with Article 18 of Regulation (EU) 2019/6
Date of completion of procedure	07/08/2024
Target species	Cattle, sheep, pigs
Indication for use	Cattle: Treatment and metaphylaxis of bovine respiratory disease (BRD) associated with *Histophilus somni, Mannheimia haemolytica* and *Pasteurella multocida*. The presence of the disease in the group should be established before the product is used. Pigs: Treatment of swine respiratory disease (SRD) associated with *Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, Glaesserella parasuis,* and *Pasteurella multocida*. Sheep: Treatment of infectious pododermatitis (foot rot) associated with virulent *Dichelobacter nodosus* and *Fusobacterium necrophorum* requiring systemic treatment.
ATCvet code	QJ01FA95
Concerned Member States	DK, ES, FR, SE, UK(NI)

PUBLIC ASSESSMENT REPORT

The public assessment report reflects the scientific conclusion reached by the Health Products Regulatory Authority (HPRA) at the end of the evaluation process and provides a summary of the grounds for approval of the marketing authorisation for the specific veterinary medicinal product. It is made available by the HPRA for information to the public, after the deletion of commercially confidential information. The legal basis for its creation and availability is contained in relevant articles of Regulation (EU) 2019/6. It is a concise document which highlights the main parts of the documentation submitted by the applicant and the scientific evaluation carried out by the HPRA leading to the approval of the product for marketing in Ireland. The Summary of Product Characteristics (SPC) for this product is available on the HPRA's website.

I. SCIENTIFIC OVERVIEW

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.
It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC.
The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.
The efficacy of the product was demonstrated according to the claims made in the SPC.
The overall benefit/risk analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

A. Qualitative and Quantitative Particulars

The product contains the active substance gamithromycin (150 mg/ml) and the excipients monothioglycerol, succinic acid and glycerol formal.
The container/closure system consists of Type I glass vials of 100 ml, 250 ml or 500 ml which are closed with a chlorobutyl rubber stopper and an aluminium seal.
The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice at a licensed manufacturing site.
Process validation data for the manufacturing process has been presented in accordance with the relevant European guidelines.

C. Control of Starting Materials

The active substance is gamithromycin, an established active substance. The active substance is manufactured in accordance with the principles of good manufacturing practice.
The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification has been provided.
Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies
There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

D. Control on Intermediate Products (pharmaceuticals)

Not applicable.

E. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.
Satisfactory validation data for the analytical methods has been provided.
Batch analytical data from the proposed production site has been provided demonstrating compliance with the specification.

F. Stability

Stability data on the active substance has been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.
Stability data on the finished product has been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

G. Other Information

Not applicable.

III SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

This application has been submitted in accordance with Article 18 of Regulation (EU) 2019/6 (generic veterinary medicinal product). The reference medicinal product cited is Zactran 150 mg/ml Solution for Injection for Cattle, Sheep and Pigs (EU/2/08/082/001-007, Boehringer Ingelheim Vetmedica GmbH) which was first authorised on 24th July 2008.

III.A Safety Testing

Pharmacological Studies

As this is a generic application according to Article 18 of Regulation (EU) 2019/6 and bioequivalence with a reference VMP has been demonstrated, results of pharmacodynamic or pharmacokinetic tests are not required.

Toxicological Studies

As this is a generic application according to Article 18 of Regulation (EU) 2019/6 and bioequivalence with a reference VMP has been demonstrated, results of toxicological tests are not required.

User Safety

A user safety assessment has been provided. The product contains the same concentration of the active substance and comparable excipients in similar amounts as the reference veterinary medicinal product. In addition, the product is intended to be administered by the same route of administration at the same dose and for the same indications for use in the same species as the reference product. Given no difference in terms of active substance and minor differences in the quantitative composition of the excipients no greater risk to the user is anticipated following use of the product than that which already exists for the reference product.
Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

Environmental Risk Assessment

The applicant has not provided an environmental risk assessment, instead, reference to the 'Reflection paper on the interpretation of Article 18(7) of Regulation (EU) 2019/6' (EMA/CVMP/ERA/622045/2020) has been made. As noted in the reflection paper, an ERA is no longer routinely required in support of a generic application, subject to a number of criteria being satisfied.
As the reference product was authorised after 1 October 2005 it is accepted that an ERA according to VICH GL38 has been performed, that the ERA data package provided has been found to be satisfactory and that the need for appropriate risk mitigation measures were considered at the time. It is accepted that an ERA is not required for the product.
Consistent with the reference product no special precautions for the protection of the environment are included on the product literature.

III.B Residues Documentation

Residue Studies

No residue depletion studies were conducted. The product contains the same concentration of the active substance and comparable excipients in similar amounts as the reference veterinary medicinal product. The CVMP Guideline on determination of withdrawal periods for edible tissues (EMA/CVMP/SWP/735325/2012 Rev.2) provides the following guidance for generic products:
"When the formulation (active and inactive ingredients), the dose schedule, the route(s) of administration and the target species of a specific generic product, are identical to a currently approved product (i.e. the reference product), or it has been adequately justified that any differences in formulation are so minor such that they will not impact on residue depletion, then the withdrawal period of the latter can be used for the former."
The product is intended to be administered by the same routes of administration, at the same dose, and for the same indications for use in the same species as the reference product. It is accepted that the formulations are qualitatively and quantitatively similar and that any differences in formulation are so minor they will not impact on residue depletion.

MRLs

Gamithromycin is included in Table 1 of the Annex to Commission Regulation (EU) No 37/2010 as follows:

Pharmacologically active substance	Marker residue	Animal Species	MRL	Target tissues	Other provisions
Gamithromycin	Gamithromycin	All ruminants, except bovine	50 µg/kg 50 µg/kg 300 µg/kg 200 µg/kg	Muscle Fat Liver Kidney	Not for use in animals producing milk for human consumption
		Bovine	20 µg/kg 200 µg/kg 100 µg/kg	Fat Liver Kidney	Not for use in animals producing milk for human consumption
		Porcine	100 µg/kg 100 µg/kg 100 µg/kg 300 µg/kg	Muscle Skin and fat Liver Kidney	

Withdrawal Periods

Based on the data provided, the following withdrawal periods are justified:
Cattle:
Meat and offal: 64 days.
Not authorised for use in animals producing milk for human consumption.
Do not use in pregnant animals which are intended to produce milk for human consumption within 2 months of expected parturition.
Sheep:
Meat and offal: 29 days.
Not authorised for use in animals producing milk for human consumption.
Do not use in pregnant animals which are intended to produce milk for human consumption within 1 month of expected parturition.
Pigs:
Meat and offal: 16 days.

IV. CLINICAL ASSESSMENT

IV.A Pre-Clinical Studies

As this is a generic application according to Article 18 of Regulation (EU) 2019/6 and bioequivalence with a reference product has been demonstrated, pre-clinical studies are not required.
The efficacy claims for this product are equivalent to those of the reference product.

Tolerance in the Target Species of Animals

No target animal tolerance studies in the target species were conducted.
The product literature accurately reflects the type and incidence of adverse effects which might be expected.

Resistance

The bibliography / information provided did not highlight any concerns in relation to development of resistance to gamithromycin in the EU region. As this is a generic application, and the product is administered to the same target species for the same indications at the same posology using the same route of administration, the potential for resistance development is expected to be equivalent to that of the reference product.
Adequate warnings and precautions appear on the product literature.

IV.B Clinical Trials

As this is a generic application according to Article 18 of Regulation (EU) 2019/6 and bioequivalence with a reference product has been demonstrated, clinical trials are not required.
The efficacy claims for this product are equivalent to those of the reference product.

V. OVERALL CONCLUSION AND BENEFIT/RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

VI. POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available in the Union Product Database (UPD).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.
None.